NADH-ubiquinone oxidoreductase chain 4 (MT-ND4) (MT-ND4)

NADH-ubiquinone oxidoreductase chain 4 (MT-ND4) is a core subunit of mitochondrial Complex I, the largest enzyme in the oxidative phosphorylation pathway (UniProt: P03905). Encoded by mitochondrial DNA, MT-ND4 is a hydrophobic protein located in the membrane arm of the complex, where it plays a vital role in proton translocation across the inner mitochondrial membrane to generate the electrochemical gradient required for ATP synthesis (NCBI Gene: 4538). Mutations in MT-ND4, specifically the m.11778G>A mutation, are the primary cause of Leber hereditary optic neuropathy (LHON), a condition leading to the selective death of retinal ganglion cells and subsequent central vision loss (StatPearls: NBK482435). Therapeutic interventions targeting MT-ND4 include gene therapies like Lumevoq (GS010), which aim to restore mitochondrial function through allotopic expression of the wild-type protein (PMID: 33164115). Beyond LHON, the broader function of Complex I is a target for metabolic regulation; for instance, the drug metformin exerts its glucose-lowering effects partly through the mild inhibition of this complex, highlighting its significance in both rare genetic disorders and common metabolic diseases (PMID: 24929250). Complex I is also a major site of reactive oxygen species production, making its regulation critical in the context of neurodegeneration and aging.

Other names

ND4MTND4NADH dehydrogenase subunit 4Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4

Gene replacement therapy (e.g., Lumevoq) utilizes an adeno-associated virus vector to deliver a functional MT-ND4 gene to the nucleus for subsequent mitochondrial import, restoring Complex I activity (PMID: 33164115). Small molecules like idebenone act as electron carriers to bypass Complex I, while metformin acts as a mild inhibitor of the complex to modulate systemic metabolism (PMID: 24929250).